...+ Bulgarian animal health company Huvepharma AD has bought out its minority shareholder, The Rohatyn Group, and financed the transaction by issuing term loans totaling 255 million. + We assess Huvepharma's business risk profile as weak and its financial risk profile as significant. + We are therefore assigning our '##-' long-term corporate credit rating to Huvepharma. + The positive outlook on Huvepharma reflects the possibility of an upgrade, given the company's sound market positions and our expectation that it will quickly reduce debt in 2014. FRANKFURT (Standard & Poor's) Nov. 7, 2014--Standard & Poor's Ratings Services today assigned its '##-' long-term corporate credit rating to Bulgaria-based Huvepharma AD, a pharmaceutical company with a focus on developing, manufacturing, and marketing animal health products and feed additives. The outlook is positive. At the same time, we assigned our '##-' issue rating to Huvepharma's 275 million senior secured credit facilities (including a...
